Flic is the Founding Partner of tranScrip. She is a respected pharmaceutical physician and has spent 4 decades in drug development. Over the last 13 years, Flic has led several MAAs, NDAs and multiple innovative projects and drug registrations for over 250 of tranScrip’s clients.
Flic has held a number of senior and CEO positions in big pharma, biotech and CROs in both Europe and North America. She has extensive experience of working on the development, submission and launches of products in infection, respiratory disease, arthritis, immunology, chronic kidney disease and oncology.
A committed entrepreneur, Flic was founding Chairman of the steering group that set-up the UK Faculty of Pharmaceutical Medicine (FPM) and recently took office as FPM President. Flic was elected to drive more interest in the treatment of infection, investment in women’s health and to support innovation in and raise standards of pharmaceutical medicine.
In 2020, Flic was awarded the Fellowship of the Academy of Medical Science and is passionate about bringing pharmaceutical medicine into mainstream medical science and its application to public health.
Flic started her career in big pharma in Rhone Poulenc (now Sanofi) and Parke Davis (now Pfizer), in the latter she held senior positions including global therapeutic head and Board level in UK and Ireland. She started Gabbay Group, a CRO acquired by PPD, was Founding Chairman of Phico Therapeutics and has been CEO of two small biotech companies. She was also Director of Education at the Drug Safety Research Unit (DSRU) in Southampton and helped set up many courses for training pharmaceutical physicians and others globally.